NCT03232567View on ClinicalTrials.gov

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

March 7, 2018

Study Completion Date

June 15, 2018

Conditions
Influenza
Interventions
BIOLOGICAL

NasoVAX

Single ascending dose study

Trial Locations (1)

20850

Optimal Health Research, Rockville

Sponsors

Lead Sponsor

Altimmune, Inc.
All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY